Inventor · disambiguated record
Douglas G. Batt
Also filed as: BATT DOUGLAS G · BATT DOUGLAS GUY
54 granted patents·5 pending applications·1,133 citations·filing 1986–2024
98Inventor score
Top patents by PatentIndex Score
59 records- 0197US5760028AIntegrin receptor antagonistsDU PONT MERCK PHARMA·Filed 1996·Granted Jun 2, 1998·161 cites·16 claims
- 0297US5593994AProstaglandin synthase inhibitorsDU PONT MERCK PHARMA·Filed 1994·Granted Jan 14, 1997·251 cites·13 claims
- 0396US10000480B2Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responsesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 19, 2018·20 cites·14 claims
- 0494US8685969B2Carboline carboxamide compounds useful as kinase inhibitorsLIU CHUNJIAN·Filed 2011·Granted Apr 1, 2014·53 cites·15 claims
- 0594US8362065B2Carbazole carboxamide compounds useful as kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2011·Granted Jan 29, 2013·32 cites·20 claims
- 0693US8084620B2Carbazole carboxamide compounds useful as kinase inhibitorsLIU QINGJIE·Filed 2009·Granted Dec 27, 2011·60 cites·22 claims
- 0790US10435369B2Tricyclic sulfones as ROR gamma modulatorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Oct 8, 2019·6 cites·6 claims
- 0890US9815859B2Tricyclic sulfones as RORγ modulatorsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Nov 14, 2017·11 cites·15 claims
- 0990US6214834B1Integrin inhibitor prodrugsDU PONT PHARM CO·Filed 1998·Granted Apr 10, 2001·57 cites·42 claims
- 1089US7163937B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Jan 16, 2007·29 cites·19 claims
- 1187US2025243193A1Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responsesBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1286US5849736AIsoxazoline and isoxazole fibrinogen receptor antagonistsDU PONT MERCK PHARMA·Filed 1995·Granted Dec 15, 1998·70 cites·31 claims
- 1385US9334290B2Substituted tetrahydrocarbazole and carbazole carboxamide compoundsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted May 10, 2016·5 cites·20 claims
- 1485US5710159AIntegrin receptor antagonistsDU PONT MERCK PHARMA·Filed 1996·Granted Jan 20, 1998·39 cites·21 claims
- 1585US5523408A2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agentsDU PONT MERCK PHARMA·Filed 1994·Granted Jun 4, 1996·32 cites·8 claims
- 1684US7482335B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Jan 27, 2009·6 cites·21 claims
- 1784US6949546B2N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB PHARMA CO·Filed 2003·Granted Sep 27, 2005·18 cites·15 claims
- 1884US6627629B2N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB PHARMA·Filed 2001·Granted Sep 30, 2003·20 cites·24 claims
- 1984US5639759ACarbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agentsDU PONT MERCK PHARMA·Filed 1995·Granted Jun 17, 1997·46 cites·16 claims
- 2083US8815840B2Carbazole and carboline kinase inhibitorsPURANDARE ASHOK VINAYAK·Filed 2009·Granted Aug 26, 2014·5 cites·6 claims
- 2183US4833164A2-substituted-1-naphthols, pharmaceutical compositions of, and their use as 5-lipoxygenase inhibitorsDU PONT·Filed 1986·Granted May 23, 1989·19 cites·51 claims
- 2282US7378409B2Substituted cycloalkylamine derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2004·Granted May 27, 2008·20 cites·9 claims
- 2376US2022356180A1Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responsesBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 2475US5093351ASubstituted indole, benzofuran and benzothiophene derivatives as 5-lipoxygenase inhibitorsDU PONT MERCK PHARMA·Filed 1989·Granted Mar 3, 1992·19 cites·18 claims
- 2574US5578609A2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agentsDU PONT MERCK PHARMA·Filed 1995·Granted Nov 26, 1996·20 cites·8 claims
- 2673US7381738B2Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Jun 3, 2008·1 cites·7 claims
- 2772US5874441ACarbocyclic and hetertocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agentsDU PONT PHARM CO·Filed 1997·Granted Feb 23, 1999·23 cites·19 claims
- 2871US6919356B2N-substituted heterocyclic amines as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Jul 19, 2005·2 cites·21 claims
- 2971US6114328AIsoxazoline and isoxazole fibrogen receptor antagonistsDU PONT PHARM CO·Filed 1997·Granted Sep 5, 2000·27 cites·49 claims
- 3069US9714234B2Carbazole carboxamide compoundsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jul 25, 2017·1 cites·9 claims
- 3168US11053197B2Carbazole derivativesBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Jul 6, 2021·0 cites·23 claims
- 3268US10676434B2Carbazole derivativesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 9, 2020·0 cites·8 claims
- 3368US6110910ACarbocyclic heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agentsDU PONT PHARM CO·Filed 1998·Granted Aug 29, 2000·18 cites·16 claims
- 3467US10435415B2Substituted tetrahydrocarbazole and carbazole carboxamide compoundsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Oct 8, 2019·0 cites·11 claims
- 3567US2019382416A1Substituted tetrahydrocarbazole and carbazole carboxamide compoundsBRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 3666US5932586AProstaglandin synthase inhibitorsDU PONT PHARM CO·Filed 1996·Granted Aug 3, 1999·21 cites·9 claims
- 3765US10106559B2Substituted tetrahydrocarbazole and carbazole carboxamide compoundsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Oct 23, 2018·0 cites·11 claims
- 3863US7829571B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Nov 9, 2010·0 cites·18 claims
- 3963US7291744B2N-ureidoalkyl-amino compounds as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Nov 6, 2007·2 cites·22 claims
- 4060US5707844AImmunoassay reagents and methods for detecting brequinar and analogsDU PONT MERCK PHARMA·Filed 1995·Granted Jan 13, 1998·7 cites·20 claims
- 4159US5428040ACarbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agentsDU PONT MERCK PHARMA·Filed 1993·Granted Jun 27, 1995·10 cites·8 claims
- 4258US8759390B2Chromene modulators of chemokine receptor activityBATT DOUGLAS G·Filed 2009·Granted Jun 24, 2014·0 cites·8 claims
- 4357US2016194338A1Substituted tetrahydrocarbazole and carbazoles carboxamide compoundsBRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
- 4454US5393891AImmunoassay reagents and methods for detecting brequinar and analogsDU PONT MERCK PHARMA·Filed 1993·Granted Feb 28, 1995·11 cites·4 claims
- 4553US10266491B2Carbazole derivativesBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Apr 23, 2019·0 cites·9 claims
- 4653US2014235672A1Chromene modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 4752US4985435A2-substituted-1-naphthols as 5-lipoxygenase inhibitorsDU PONT·Filed 1989·Granted Jan 15, 1991·2 cites·18 claims
- 4851US5049570APyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activityDU PONT MERCK PHARMA·Filed 1990·Granted Sep 17, 1991·4 cites·54 claims
- 4949US8507559B2Cyclohexenyl modulators of chemokine receptor activityCARTER PERCY H·Filed 2009·Granted Aug 13, 2013·0 cites·16 claims
- 5045US7479496B2Substituted spiro azabicyclics as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Jan 20, 2009·0 cites·11 claims
Showing the top 50 of 59 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Douglas G. Batt files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →